Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4

Featuring perspectives from Dr Richard Penson, including the following topics: Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00) Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28) Case: A woman in her late 30s with Stage IIC BRCA wild-type HGSOC who undergoes surgery and receives carboplatin/paclitaxel (LOH-negative) — Dana M Chase, MD (24:39) Case: A woman in her early 60s with Stage IIIC HGSOC and a germline BRCA1 mutation who receives IV/IP paclitaxel/cisplatin — Paul DiSilvestro, MD (28:11) Case: A woman in her early 60s with BRCA wild-type, HRD-negative peritoneal cancer who received neoadjuvant and adjuvant carboplatin/paclitaxel and now presents with altered mental status and a cerebellar metastasis — Karim ElSahwi, MD (34:40) Faculty Survey (40:37) Case: A woman in her early 70s with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a germline PALB2 mutation develops breast cancer during maintenance niraparib — Dr Chase (50:02) Case: A woman in her late 60s with Stage IV BRCA wild-type, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab — Priya Rudolph, MD (59:25) CME information and select publications